ISMP Medication Safety Alert!®

Long-Term Care AdviseERR

Providing a valuable resource to reduce medication error risk in the long-term care setting

The ISMP Medication Safety Alert!® Long-Term Care AdviseERR is a digital bulletin, published bi-monthly for practitioners who work in a long-term care facility or with long-term care residents. 

Who reads this newsletter? 

  • Nurses
  • Pharmacists
  • Physicians
  • Long-term care facility staff
  • Anyone concerned with medication safety 

Subscription Options

Online access to six (6) issues per year. Subscriptions start with the first issue after the date of purchase. You will receive a reminder notice via email to renew your annual subscription before your subscription expires. Your subscription will not automatically renew.
Access to back issues are not included. Single issues are available for purchase. 

Academic-based subscription: contact ISMP for pricing

Pharmaceutical Industry subscription: contact ISMP pricing


 

Personal Subscription

Subscription Information

  • $52.00 per year

  • Online access for one (1) user

  • No re-distribution is permitted

Single Site Subscription

Subscription Information for healthcare organizations

  • $80.00 per year

  • Online access for up to 50 users within a single site organization

  • Permission to re-distribute within single-site location

  • Instructions to add users to a subscription will be emailed to the user purchasing the subscription

  • Please use your organization email address when subscribing

  • Multi-site organizations: contact ISMP for pricing

Browse Issues

This month's main topic: What Price Must We Pay for Safety? Excessive Cost of EPINEPHrine Auto-Injectors Leads to Error-Prone Use of Ampuls or Vials
This month's main topic: Selected Medication Safety Risks to Manage in 2016 That Might Otherwise Fall Off the Radar Screen. Part II.
This month's main topic: Intravenous (IV) Infusion Therapy in the Long-Term Care Setting: Not Without Resident Safety Risks
This month's main topic: Severe Harm and Death Associated with Medication Errors and Drug-Drug Interactions Involving Low-Dose Oral Methotrexate